SDZ-ASM-981. Topical treatment for inflammatory skin diseases

Drugs of the Future

Volumn 23, Issue 5, 1998, Pages 508-512

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

12 [2 (4 CHLORO 3 METHOXYCYCLOHEXYL) 1 METHYLVINYL] 17 ETHYL 1,14 DIHYDROXY 23,25 DIMETHOXY 13,19,21,27 TETRAMETHYL 11,28 DIOXA 4 AZATRICYCLO[22.3.1.0 4,9]OCTACOS 18 ENE 2,3,10,16 TETRAONE; 3 [2 (4 CHLORO 3 METHOXYCYCLOHEXYL) 1 METHYLVINYL] 15,19 EPOXY 8 ETHYL 15,19 DIHYDROXY 14,16 DIMETHOXY 4,10,12,18 TETRAMETHYL DOCOSAHYDRO 3H PYRIDO[2,1 C][1,4]OXAAZACYCLOTRICOSINE 17,20,21 TETRAONE; ANTIINFLAMMATORY AGENT; ASCOMYCIN; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; LACTAM DERIVATIVE; MACROLIDE; PIMECROLIMUS; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALOPECIA AREATA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG FORMULATION; DRUG MECHANISM; DRUG SYNTHESIS; ECZEMA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SKIN ATROPHY; SKIN INFLAMMATION; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION;

EID: 2642676855     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.05.457487     Document Type: Review

References (20)

1. Okuhara, M., Tanaka, H., Goto, T., Kino, T., Hatanaka, H. (Fujisawa Pharm. Co., Ltd.). Tricyclo cpds., a process for their production and pharmaceutical compsn. containing the same. EP 184162.
2. Bauman, K., Emmer, G. (Sandoz, Ltd.; Sandoz Patent GmbH; Sandoz Erfindungen VmbH). Heteroatoms-containing tricyclic cpds. AU 9165843, EP 427680, JP 91223291, US 5352671.
3. Reitamo, S. Immunomodulatory drugs. J Eur Acad Dermatol Venereol 1997, 9(Suppl. 1): Abst C059.
4. Stütz, A., Grassberger, M., Meingassner, J.G. SDZ ASM 981 - A novel anti-inflammatory macrolactam. J Eur Acad Dermatol Venereol 1997, 9(Suppl. 1): Abst S254.
5. Beveca, D., Schuler, W., Schulz, M., Werner, F., Winiski, A., Wolff, B., Zenke, G., Grassberger, M. SDZ ASM 981 - A novel anti-inflammatory macrolactam: Pharmacological activities in vitro. Australas J Dermatol 1997, 38(Suppl. 2): Abst 5244.
6. Hultsch, T., Mueller, K.D., Meingassner, J.G., Knop, J.G. SDZ ASM 981 - a novel anti-inflammatory macrolactam - inhibits FcεRI-mediated mast cell activation. Australas J Dermatol 1997, 38(Suppl. 2): Abst 5249.
7. Meingassner, J.G., Grassberger, M., Fahrngruber, H., Moore, H.D., Schuurman, H., Stütz, A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Brit J Dermatol 1997, 137: 568-76.
8. Meingassner, J.G., Fahmgruber, H., Bavandi, A., Grassberger, M. SDZ ASM 981 - a novel anti-inflammatory macrolactam - has high topical and systemic activity in animal models of skin inflammation. Australas J Dermatol 1997, 38(Suppl. 2): Abst 5258.
9. Meingassner, J.G., Kowalsky, E., Grassberger, M., Oliver, R.F. SDZ ASM 981 - a novel anti-inflammatory macrolactam - causes regrowth of hair alopecic DEBR rats after topical application. Australas J Dermatol 1997, 38(Suppl. 2): Abst 5259.
10. Meingassner, J.G., Schmook, F., Schatz, F. Pilot studies on local and systemic side effects of SDZ ASM 981 in laboratory animals. 12th Annu Meet Skin Pharmacol Soc (Nov 2-5, Vienna) 1995, Abst P 10.
11. Meingassner, J.G., Helm, A., Vit, P., Grassberger, M. SDZ ASM 981 - a novel anti-inflammatory macrolactam - does not induce skin atrophy. Australas J Dermatol 1997, 38(Suppl. 2): Abst 5243.
12. Queille-Roussel, C., Graeber, M., Wagenaar, A., Thurston, M., Lachapelle, J.M., Decroix, J., De Cuyper, C., Ortonne, J.P. Topical treatment with the anti-inflammatory macrolactam SDZ ASM 981 inhibits established nickel contact dermatitis. Australas J Dermatol 1997, 38(Suppl. 2): Abst 3039.
13. Van Leent, E.J.M., Gräber, M., Thurston, M., Wagenaar, A., Spuls, P.I., Bos, J.D. Topical treatment with the macrolactam SDZ ASM 981 is effective in atopic dermatitis. Australas J Dermatol 1997, 38(Suppl. 2): Abst 4134.
14. Mrowietz, U., Bräutigam, M., Gräber, M., Thurston, M., Wagenaar, A., Wiedinger, G., Christophers, E. Topical treatment with the anti-inflammatory macrolactam SDZ ASM 981 suppresses plaque-type psoriasis. Australas J Dermatol 1997, 38(Suppl. 2): Abst 2056.
15. SDZ-ASM-981 development status. Novartis Company Communication April 21, 1998.
16. Guitard, P., Haeberlin, B., Link, R., Richter, F. (Sandoz, Ltd.; Sandoz Patent GmbH; Sandoz Erfindungen VmbH). Pharmaceutical compsns. WO 9703654.
17. Cottens, S., Haeberlin, B., Sedrani, R., Vonderscher, J. (Sandoz, Ltd.; Sandoz Patent GmbH; Sandoz Erfundungen, VmbH). Pharmaceutical compsns. WO 9613273.
18. Jackman, M., Popp, X.-P., Richter, F., Schmook, F. (Sandoz. Ltd.; Sandoz Patent GmbH; Sandoz Erfindungen VmbH). Pharmaceutical compsns WO 9613249.
19. Meingassner, J.G., Baumann, K., Emmer, G., Enz, A., Grassberger, M., Schuler, W., Winiski, A., Zenke, G. Pharmacological profile of SDZ ASM 981, a new antiinflammatory drug for topical use in immunologically mediated skin diseases. 12th Annu Meet Skin Pharmacol Soc (Nov 2-5, Vienna) 1995, Abst P 09.
20. Baumann, K., Grassberger, M., Meingassner, J.G., Schön, G., Schuurman, H.J. SDZ ASM 981, a new antiinflammatory drug for use in immunologically mediated skin diseases: Activities in animal models. Clin Dermatol 2000 (May 28-31, Vancouver) 1996, Abst 602.